Inhibition of integrin α vβ 3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 296, Issue 3, 2009, Pages

  Willis Kiessling, J ^a   Cines, Douglas B ^a   Higazi, Abd Al Roof ^a,b   Armstead, William M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

Cerebral circulation; Newborn; Signal transduction

Indexed keywords

AMINO ACID DERIVATIVE; ANTIBODY; ARGINYLGLYCYLASPARTYL DEXTRO PHENYLALANYLVALINE; ARGINYLGLYCYLASPARTYLGLUTAMINYLSERINE ACETIC ACID; ARGINYLGLYCYLASPARTYLSERINE; INTEGRIN ALPHAVBETA3 ANTIBODY; ISOPRENALINE; UNCLASSIFIED DRUG; UROKINASE; VITRONECTIN RECEPTOR; ARGINYL GLYCYL ASPARTYL SERINE; ARGINYL-GLYCYL-ASPARTYL-SERINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLOPEPTIDE; OLIGOPEPTIDE; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN BLOOD VESSEL; BRAIN HYPOXIA; BRAIN ISCHEMIA; CARBON DIOXIDE TENSION; CEREBROSPINAL FLUID ANALYSIS; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HEART HEMODYNAMICS; HYPERCAPNIA; HYPOTENSION; MALE; MEAN ARTERIAL PRESSURE; NEWBORN; NONHUMAN; PIA ARTERY; PIGLET; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASODILATATION; ANIMAL; BRAIN CIRCULATION; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PATHOPHYSIOLOGY; SWINE;

ADRENERGIC BETA-AGONISTS; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYPERCAPNIA; HYPOTENSION; HYPOXIA-ISCHEMIA, BRAIN; INTEGRIN ALPHAVBETA3; ISOPROTERENOL; MALE; OLIGOPEPTIDES; PEPTIDES; PEPTIDES, CYCLIC; SIGNAL TRANSDUCTION; SWINE; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VASOCONSTRICTION; VASODILATION;

EID: 64049102740     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01141.2008     Document Type: Article

References (35)

1. 3 mediate tPA activation of smooth muscle cells. Am J Physiol Heart Circ Physiol 291: H1351-H1359, 2006.
2. Armstead WM. NOC/oFQ and NMDA contribute to piglet hypoxic ischemic hypotensive cerebrovasodilation impairment. Pediatr Res 51: 586-591, 2002.
3. Armstead WM, Cines DB, Bdeir K, Kulikovskaya I, Stein SC, Higazi A. uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK. Brain Res 1231: 121-131, 2008.
4. Armstead WM, Cines DB, Higazi AA. Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig. Stroke 36: 2265-2269, 2005.
5. Armstead WM, Cines DB, Higazi AA. Plasminogen activators contribute to age dependent impairment of NMDA cerebrovasodilation after brain injury. Dev Brain Res 156: 139-146, 2005.
6. 3-targeted molecular probe for optical imaging of tumor. Bioorg Med Chem 13: 3763-3771, 2005.
7. DeVeber G, Andrew M. Cerebral sinovenous thrombosis in children. N Engl J Med 345: 417-423, 2001.
8. Ferriero DM. Neonatal brain injury. N Engl J Med 351: 1985-1995, 2004.
9. Gunther G, Junker R, Strater R, Schobess R, Kurnik K, Kosch A, Nowak-Gottl U. Symptomatic ischemic stroke in full-term neonates. Stroke 31: 2437-2441, 2000.
10. Haj-Yehia A, Nassar T, Sachais BS, Kuo A, Bdeir K, Al Mehdi AB, Mazar A, Cines DB, Higazi AA. Urokinase-derived peptides regulate vascular smooth muscle contraction in vitro and in vivo. FASEB J 14: 1411-1422, 2000.
11. Hayashi T, Sakai K, Sasaki C, Zhang WR, Warita H, Abe K. c-JUN N-terminal kinase (JNK) and JNK interacting protein response in rat brain after transient middle cerebral artery occlusion. Neurosci Lett 284: 195-199, 2000.
12. Heistad HD. What's new in the cerebral microcirculation? Microcirculation 8: 365-375, 2001.
13. Higazi AA, Bdeir K, Hiss E, Arad S, Kuo A, Barghouti I, Cines DB. Lysis of plasma clots by urokinase-soluble urokinase receptor complexes. Blood 92: 2075-2083, 1998.
14. Higazi AA, Mazar A, Wang J, Reilly R, Henkin J, Kniss D, Cines D. Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. Blood 87: 3545-3549, 1996.
15. Higazi AA, Upson RH, Cohen RL, Manuppello J, Bognacki J, Henkin J, McCrae KR, Kounnas MZ, Strickland DK, Preissner KT, Lawler J, Cines DB. Interaction of single chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins. Blood 88: 542-551, 1996.
16. Hosomi N, Jucero J, Heo JH, Koziol JA, Copeland BR, del Zoppo GJ. Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion. Stroke 32: 1341-1348, 2001.
17. Jagolino AL, Armstead WM. PTK MAPK, and NOC/oFQ impair hypercapnic cerebrovasodilation after hypoxia/ischemia. Am J Physiol Heart Circ Physiol 284: H101-H107, 2003.
18. Kim YH, Park JH, Hong SH, Koh JY. Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator. Science 284: 647-650, 1999.
19. Kraus FT, Acheen VI. Fetal thrombotic vasculopathy in the placenta: cerebral thrombi and infarcts, coagulopathies, and cerebral palsy. Hum Pathol 30: 759-769, 1999.
20. 3, integrins. J Leukoc Biol 78: 937-946, 2005.
21. Leffler CW, Busija DW, Armstead WM, Mirro R, Beasley DG. Ischemia alters cerebral vascular responses to hypercapnia and acetylcholine in piglets. Pediatr Res 25: 180-183, 1989.
22. Leffler CW, Busija DW, Beasley DG, Armstead WM, Mirro R. Postischemic micro-vascular cerebral responses to norepinephrine and hypotension in newborn pigs. Stroke 20: 541-546, 1989.
23. Mogford JE, Davis GE, Platts SH, Meininger GA. vascular smooth muscle alpha v beta 3 integrin mediates arteriolar vasodilation in response to RGD peptides. Circ Res 79: 821-826, 1996.
24. Nassar T, Haj-Yehia A, Akkawi S, Kuo A, Bdeir K, Mazar A, Cines DB, Higazi AA. Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction. J Biol Chem 277: 40499-40504, 2002.
25. Nelson KB, Lynch JK. Stroke in newborn infants. Lancet Neurol 3: 150 -158, 2004.
26. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, Vivien D, Buisson A. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor mediated signaling. Nat Med 7: 59-64, 2001.
27. 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 6: 105-119, 2003.
28. Okada Y, Copeland BR, Hamann GF, Koziol JA, Cheresh DA, del Zoppo GJ. Integrin alphavbeta3 is expressed in selected microvessels after focal cerebral ischemia. Am J Pathol 149: 37-44, 1996.
29. 3 reduces blood brain barrier breakdown in focal ischemia in rats. J Neurosci Res 84: 1837-1847, 2006.
30. 3 ameliorates focal cerebral ischemic damage in the rat middle cerebral artery occlusion model. Stroke 37: 1902-1909, 2006.
31. Sughrue ME, Mehra A, Connolly ES Jr, D'Ambrosio AL. Antiadhesion molecule strategies as potential neuroprotective agents in cerebral ischemia: a critical review of the literature. Inflamm Res 53: 497-508, 2004.
32. Tarui T, Nakakura J, Majumdar M, Andronicos N, Tagaki J, Mazar AP, Bdeir K, Kuo A, Yarovoi SV, Cines DB, Takada Y. Direct interaction of the kringle domain of urokinase type plasminogen activator with B1/3 integrins. Thromb Haemost 95: 524-534, 2006.
33. Volpe JJ. Brain injury in the premature infant: overview of clinical aspects, neuropathology, and pathogenesis. Semin Pediatr Neurol 5: 135-151, 1998.
34. Wang YF, Tsirka SE, Strickland S, Stiege PE, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 4: 228 -231, 1998.
35. Zhang L, Zhang ZG, Zhang C, Zhang RI, Chopp M. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intraarterial tenecteplase tissue plasminogen activator in a rat stroke model. Stroke 35: 2890-2895, 2004.